US Bancorp’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

US Bancorp’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25	Closed	–	–	3757
2019 Q1	$0	Hold	25	–	–	﹤0.01%	3773
2018 Q4	$0	Hold	25	–	–	﹤0.01%	3832
2018 Q3	$0	Hold	25	–	–	﹤0.01%	3795
2018 Q2	$0	Hold	25	–	–	﹤0.01%	3799
2018 Q1	$0	Hold	25	–	–	﹤0.01%	3807
2017 Q4	$0	Hold	25	–	–	﹤0.01%	3775
2017 Q3	$0	Hold	25	–	–	﹤0.01%	3726
2017 Q2	$0	Hold	25	–	–	﹤0.01%	3690
2017 Q1	$1K	Hold	25	–	–	﹤0.01%	3524
2016 Q4	$1K	Hold	25	–	–	﹤0.01%	3511
2016 Q3	$1K	Hold	25	–	–	﹤0.01%	3500
2016 Q2	$1K	Hold	25	–	–	﹤0.01%	3521
2016 Q1	$2K	Hold	25	–	–	﹤0.01%	3413
2015 Q4	$2K	Buy	+25	New	+$1.76K	﹤0.01%	3482

Other funds holding MACK

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

US Bancorp's MACK Position: Q2 2019 in Review

US Bancorp sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2019, closing a stake of 25 shares.

US Bancorp first reported a position in MACK in Q4 2015 and held it in 14 quarters. The position peaked at $2K in Q1 2016. 50 funds tracked by Wall St. Rank hold MACK as of Q2 2019.

US Bancorp reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
US Bancorp sold 25 Merrimack Pharmaceuticals, Inc. shares in Q2 2019.
US Bancorp first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
US Bancorp's Merrimack Pharmaceuticals, Inc. position peaked at $2K in Q1 2016.
50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2019.

Based on US Bancorp's 13F filing for Q2 2019, filed 13 Aug 2019.